Please login to the form below

Not currently logged in
Email:
Password:

G-BA

This page shows the latest G-BA news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

Europe responding to gene therapy challenge, but picture remains fragmented

The new law would give Germany’s G-BA ( or Federal Joint Committee the key market access decision-maker for the country) powers to dictate to the industry the data requirements

Latest news

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • The price is right? The price is right?

    The company is obliged to submit an application for the assessment of potential additional benefit, providing the G-BA with a value dossier to be evaluated by IQWiG. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    PME that it currently has no other commissions from the G-BA to assess other biologic products.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A key step is a positive assessment by the G-BA of a drug's added benefit relative

  • Oncology drugs under AMNOG: part one Oncology drugs under AMNOG: part one

    Instead, they are reimbursed at the manufacturer's price only during the first year on the market, while the Federal Joint Committee (G-BA) assesses the new product or indication for ... The G-BA also rules on the strength of evidence of the added benefit

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    IQWiG's recommendation is not final, however, and once an evidence report is create, it is then passed to a public legal entity called the Federal Joint Committee (G-BA). ... There is a hearing at G-BA in which criticism can be discussed,” she says.

More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    The G-BA also rules on the strength of evidence of the added benefit. ... explore other options to better address the likely requirements of the G-BA.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics